Chevy Chase Trust Holdings LLC buys 11,159 shares of United Therapeutics Co. (NASDAQ:UTHR)

VaselineAugust 24, 2024

0 4 minutes read

Chevy Chase Trust Holdings LLC acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 11,159 shares of the biotechnology company’s stock, valued at approximately $3,555,000.

Several other hedge funds have recently modified their holdings of UTHR. Norges Bank acquired a new position in United Therapeutics during the fourth quarter valued at $100,519,000. Swedbank AB bought a new stake in shares of United Therapeutics in the first quarter valued at about $97,316,000. Nordea Investment Management AB boosted its stake in United Therapeutics by 677.6% in the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after acquiring an additional 262,222 shares in the last quarter. Avidity Partners Management LP bought a new position in United Therapeutics in the fourth quarter valued at about $52,158,000. Finally, Canada Pension Plan Investment Board raised its position in United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares during the last quarter. Institutional investors own 94.08% of the company’s shares.

Insider buying and selling

In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. The transaction was disclosed in a legal filing with the SEC, which is available via this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $272.48, for a total transaction of $980,928.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $35,422.40. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 25,000 shares of United Therapeutics stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $833,350.26. The disclosure for this sale can be found here. Insiders sold 122,266 shares of company stock worth $38,604,580 in the last quarter. 12.50% of shares are owned by company insiders.

United Therapeutics stock fell 1.3%

Want more great investment ideas?

NASDAQ UTHR opened at $346.87 on Friday. The company has a market cap of $15.43 billion, a price-to-earnings ratio of 16.40, a PEG ratio of 1.16 and a beta of 0.55. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $353.49. The company has a current ratio of 4.35, a quick ratio of 4.18, and a debt-to-equity ratio of 0.02. The company has a 50-day moving average of $323.09 and a 200-day moving average of $271.60.

United Therapeutics (NASDAQ:UTHR – Get Free Report ) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’ revenue rose 19.8% year-over-year. In the same period last year, the firm earned $5.24 per share. On average, equities research analysts expect that United Therapeutics Co. to post 24.79 earnings per share for the current fiscal year.

Analysts set new price targets

A number of research firms recently issued reports on UTHR. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $310.00 to $321.00 in a research report on Thursday , July 11. UBS Group boosted their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. Finally, LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Moderate Buy” and a consensus price target of $334.45, according to MarketBeat .

Check out our latest research report on UTHR

About United Therapeutics

(Free report)

United Therapeutics Corporation, a biotechnology company, is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, a dry powder inhaled through prefilled, disposable cartridges; Tyvaso, a solution inhaled through an ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to reduce symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in patients with PAH; and Adcirca, an oral PDE-5 inhibitor to improve exercise capacity in patients with PAH.